BIO
Bio-Rad Laboratories, Inc.
Stock
$369.14+13.57 (+3.82%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $493M | $532M | $455M | $375M | $194M | $669M | $585M | $458M | $285M | $104M | $216M | $186M | $273M | $169M | $266M | $263M | $226M | $325M | $191M |
| Capital expenditures | $140M | $158M | $166M | $157M | $113M | $134M | $109M | $99M | $130M | $111M | $141M | $112M | $121M | $107M | $143M | $103M | $88M | $68M | — |
| Free cash flow | $353M | $375M | $290M | $218M | $82M | $536M | $476M | $359M | $156M | −$7.2M | $75M | $74M | $152M | $62M | $124M | $160M | $137M | $257M | — |
| Stock-based compensation | $60M | $58M | $62M | $61M | $61M | $51M | $42M | $36M | $28M | $23M | $20M | $17M | $15M | $14M | $13M | $11M | $10M | $9.1M | — |
| Buybacks | $133M | $296M | $204M | $429M | $216M | $50M | $100M | $28M | $49M | $2.9M | $0 | $0 | $0 | $0 | $101K | $0 | $0 | — | — |
| Free cash flow margin | 13.6% | 14.5% | 11.3% | 8.2% | 2.9% | 18.3% | 18.7% | 15.5% | 6.8% | −0.3% | 3.6% | 3.7% | 7.0% | 2.9% | 6.0% | 7.7% | 7.1% | 14.4% | — |